Psoriasis
Conditions
Interventions
Control group:Topical application of Dalixin (Calcipotriol Ointment, LEO Laboratories Limited
15 g containing 0.75 mg of active ingredient) to the affected areas, twice daily for a total treatment duration of 8 weeks, followed by an 8-week follow-up period.
Experimental group:Topical application of liquiritin cream (3%: 15 g) to the affected areas, twice daily for a total treatment duration of 8 weeks, followed by an 8-week follow-up period.
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meet the Western medical clinical diagnostic criteria for plaque psoriasis; 2. Body surface area (BSA) affected by psoriasis lesions is less than 10%; 3. Age between 18 and 70 years (inclusive) with no gender restrictions; 4. Participants have a full understanding of the trial content voluntarily agree to participate in the trial and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals with other active skin diseases that may interfere with the assessment of the condition. 2. Individuals who have previously received treatment with etanercept infliximab ixekizumab adalimumab guselkumab ustekinumab or secukinumab and have discontinued these medications for =14 days 40 days 52 days 64 days 72 days 84 days or 108 days respectively; or those who have previously received treatment with JAK inhibitors and have discontinued for =1 week. 3. Individuals currently experiencing severe uncontrollable local or systemic acute or chronic infections. 4. Individuals currently suffering from severe diseases that cannot be controlled with conventional medications such as cardiovascular respiratory gastrointestinal urological hematological or psychiatric disorders; or patients with clinical laboratory test results falling into any of the following categories: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels elevated by >1.5 times the upper limit of normal; serum creatinine levels elevated by >1.5 times the upper limit of normal; any of the main hematological parameters (white blood cell count red blood cell count hemoglobin level platelet count) below the lower limit of normal; or other laboratory abnormalities deemed by the investigator as unsuitable for participation in this trial. 5. Individuals with a history of malignancy primary or secondary immunodeficiency or hypersensitivity; or those with a family history of cancer. 6. Individuals who have undergone major surgery within the past 8 weeks or who are expected to require such surgery during the study period. 7. Pregnant or breastfeeding patients. 8. Individuals with a history of alcoholism drug abuse or medication misuse. 9. Patients known to be allergic to any of the medications used in this study or those who are intolerant to topical treatments with vitamin D3 derivatives or traditional Chinese medicine preparations. 10. Individuals deemed by the investigator to be otherwise unsuitable for participation in this study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Effective Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse Assessment;Dermatology Life Quality Index;Body Surface Area;Physician's Global Assessment; | — |
Countries
China
Contacts
Public ContactMi Zhou
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Outcome results
None listed